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Background: This study was performed to evaluate the tolerability
and efficacy of temozolomide and irinotecan as a second-line regi-
men in recurrent/metastatic non–small cell lung cancer (NSCLC).
Methods: Patients with recurrent/metastatic NSCLC, including
those with treated brain metastases, following one prior platinum-
based regimen received temozolomide 75 mg/m2 daily on days 1
through 15 and irinotecan 100 mg/m2 on days 8 and 15 every 21
days.
Results: The authors treated 46 patients, of whom more that 90%
had a performance status of 0 or 1. Four patients (8.7%) attained
partial response and 17 (37.0%) had disease stabilization as their
best response. The median time to progression was 1.8 months,
median overall survival was 9.8 months, and 1-year overall survival
was 34%. Grade 1/2 fatigue (63%), anemia (61%), nausea (52%),
and diarrhea (44%) were the most common toxicities. Grade 3/4
leukopenia and diarrhea were each observed in 9% of patients. One
unexpected death occurred, possibly related to the regimen.
Conclusion: Second-line treatment with temozolomide and irinote-
can showed tolerable toxicities. The response rates, median survival
times, and 1-year survival rates were comparable to other active
NSCLC agents.
Key Words: Non–small cell lung cancer, Metastasis, Temozolo-
mide, Irinotecan.
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Lung cancer is the leading cause of cancer mortality in theUnited States. Approximately 172,000 new lung cancer
cases and 164,000 deaths were expected in 2005.1 World-
wide, there were 10 million newly diagnosed lung cancers in
the year 2000.2 Non–small cell lung cancer (NSCLC) ac-
counts for the majority of lung cancers, and approximately 70
to 80% of patients with NSCLC present with locally ad-
vanced or metastatic disease.1 Almost all patients with locally
advanced or metastatic disease will relapse within a short
time after initial treatment. U.S. Food and Drug Administra-
tion–approved second-line agents—docetaxel,3 pemetrexed,4
and erlotinib5—produce response rates of approximately
10%, with a median survival of 8 months. Furthermore, 30 to
40% of NSCLC patients have brain metastasis during the
course of their disease, resulting in significant morbidity.6,7
Brain metastases are believed to occur because of the inabil-
ity of most chemotherapy agents to cross the blood-brain
barrier.
Temozolomide is an orally administered prodrug that is
converted spontaneously to the active alkylating agent mono-
methyl triazenoimidazole carboxamide at physiologic pH.8
Temozolomide is able to cross the blood-brain barrier and
reaches therapeutic concentrations in the cerebrospinal fluid.9
Currently, temozolomide is standard therapy in patients with
refractory anaplastic astrocytomas.10,11 It is also effective in
primary brain tumors when given concurrently with radiation
therapy in the first-line setting.12 Monotherapy temozolomide
has activity against brain metastasis from a variety of solid
tumors including NSCLC,13,14 and the effect of radiotherapy
is enhanced by temozolomide.12,15,16 Furthermore, temozolo-
mide has demonstrated some single-agent activity in the
second-line setting in NSCLC.17
Temozolomide exerts its effect by methylating the
O6-position in the guanine residue, producing O6-methylgua-
nine, which is paired to thymine. This abnormal pair is
recognized by the mismatch repair system, and in the process
of removing the methylated guanine residue, apoptosis oc-
curs.18 Apart from the mismatch repair system, the O6-
methylguanine residue can be removed by an intranuclear
enzyme called O6-methylguanine-DNA-methyltransferase
(MGMT).19,20 Temozolomide resistance has been correlated
with high levels of MGMT.19–21 Overcoming such resistance
may increase the activity of temozolomide. It has been shown
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that the level of MGMT decreases progressively with each
dose of temozolomide (as DNA damage is repaired).22 Thus,
an extended administration schedule of temozolomide should
result in a cumulative and sustained depletion of MGMT.
When temozolomide was administered in recurrent glioma
patients for 6 to 7 weeks at 75 mg/m2 per day, the regimen
was well tolerated and the major toxicity was reversible
marrow suppression (neutropenia and thrombocytopenia).23
This regimen resulted in a twofold higher drug exposure over
4 weeks (2100 versus 1000 mg/m2 over 4 weeks) compared
with the conventional dosing of 150 to 200 mg/m2 per day for
5 days every 28 days. Furthermore, with a response rate of
33% in recurrent glioma patients, the extended dosing sched-
ule compared favorably with the conventional schedule.24
Other groups have confirmed that temozolomide at 75 to 100
mg/m2 per day for 3 weeks repeated every 4 weeks was well
tolerated and resulted in marked reduction in MGMT lev-
els.25,26
In an attempt to increase the activity of temozolomide,
we combined it with irinotecan using the extended dosing
schedule of temozolomide. Irinotecan, a derivative from the
Camptotheca acuminata tree, inhibits DNA and RNA syn-
thesis through DNA topoisomerase I inhibition.27 Irinotecan
is a standard chemotherapy in colorectal cancer.28 In small-
cell lung cancer, the combination of cisplatin and irinotecan
has demonstrated significant efficacy.29 Irinotecan in combi-
nation with a platinum agent as first-line therapy in NSCLC
is efficacious and well tolerated.30,31 In the second-line set-
ting, irinotecan in combination with other cytotoxic chemo-
therapies has also demonstrated activity in exploratory tri-
als.32,33
Irinotecan has synergistic activity when combined with
alkylating agents34 and with temozolomide specifically.35,36
The formation of O6-methylguanine by temozolomide results
in recruitment of topoisomerase I37. This increases the
chances of a topoisomerase I inhibitor such as irinotecan to
bind and stabilize the cleavage complex, leading to further
DNA damage. The combination of temozolomide and irino-
tecan was well tolerated in phase I dose-escalation studies.38
In patients with recurrent gliomas, the combination demon-
strated favorable response rates and low toxicity rates, with
grade 4 leukopenia and thrombocytopenia occurring in 3%
and 6% of patients, respectively, and no nonhematologic
grade 3 or 4 toxicities were seen.39 With enhanced activity
demonstrated in preclinical studies, nonoverlapping toxici-
ties, and encouraging clinical results, we conducted a multi-
center phase II trial combining temozolomide and irinotecan
as second-line therapy in advanced NSCLC.
PATIENTS AND METHODS
Study Subjects
Patients with histologically or cytologically confirmed
NSCLC with disease progression after one prior platinum-
based chemotherapy regimen were included in the study. All
patients were older than 18 years; had an Eastern Cooperative
Oncology Group performance status of 0 to 2; and adequate
hematologic (white blood cell count  3000 cells/l, abso-
lute neutrophil count  1500 cells/l, platelet count 
100,000 cells/l), hepatic (total bilirubin within normal in-
stitutional limits, serum transaminases  2.5 times the insti-
tutional upper limit of normal), and renal (creatinine clear-
ance  60 ml/min) function. All patients were also required
to have at least one measurable lesion on computed tomo-
graphic scanning. Patients with treated (radiation or surgery)
or asymptomatic brain metastasis were eligible for the study,
provided they were on a stable or downward tapering dose of
steroids.
Patients on phenytoin were excluded because phenyt-
oin up-regulates irinotecan metabolism, leading to lower
plasma concentrations of irinotecan.40 At least 4 weeks had to
have elapsed from completion of the last cycle of chemother-
apy before commencing the trial. Other exclusion criteria
were prior treatment with temozolomide or irinotecan; un-
controlled intercurrent illness including but not limited to
active infections, symptomatic congestive heart failure, un-
stable angina pectoris, cardiac arrhythmia, or psychiatric
illness that would limit compliance with the study require-
ments; pregnancy; and immunodeficiency syndromes.
Study Design
The primary objective of this multicenter single-arm
phase II trial was to assess the therapeutic activity of temo-
zolomide and irinotecan in NSCLC as second-line therapy.
The primary endpoint was overall response rate. Secondary
endpoints were survival, time to disease progression, and
toxicity.
The accrual plan for the study was to enroll the first six
patients at the University of Chicago Medical Center at the
initial dose level of temozolomide administered orally, 75
mg/m2 daily on days 1 through 15, and irinotecan adminis-
tered intravenously, 100 mg/m2 on days 8 and 15 of a 21-day
cycle. After the first six patients developed no unexpected
toxicities, subsequent patients were treated with the same
doses and schedule.
Patients were instructed to take temozolomide at bed-
time after a 2-hour fast and to continue fasting for at least 1
hour after taking temozolomide. Patients recorded the exact
time and dose temozolomide was taken on a case report form.
Irinotecan was administered in the outpatient setting by
intravenous infusion over 90 minutes in 250 ml of 5%
dextrose.
Baseline and Follow-Up Assessment
Baseline assessments included complete medical his-
tory, physical examination, complete blood count, and serum
complete metabolic panel. Because temozolomide is associ-
ated with an increased risk of Pneumocystis pneumonia,41
patients on corticosteroids received trimethoprim/sulfame-
thoxazole 160/800 mg administered orally twice daily every
Saturday and Sunday as prophylaxis. Patients were assessed
for tumor response after every two cycles. Response and
progression were evaluated using the Response Evaluation
Criteria in Solid Tumors committee criteria.
In patients showing disease stabilization or objective
response, the regimen was repeated every 21 days to a
maximum of six cycles. For all patients who achieved a
partial response (PR) or a complete response, confirmation by
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repeat assessments was required 6 weeks after the criteria for
response was met. In the case of stable disease (SD), fol-
low-up measurements had to meet the SD criteria after at
least a 6-week interval.
The Common Terminology Criteria for Adverse Events
of the National Cancer Institute (NCI) version 2.0 was used
for toxicity assessment. Doses of chemotherapy were modi-
fied according to any hematologic and nonhematologic ad-
verse effects.
Dose reductions for hematologic and nonhematologic
toxicities except for diarrhea, alopecia, asthenia, nausea, and
vomiting were as follows: grade 1 toxicity, no dose reduction;
grade 2 toxicity, 25% dose reduction in temozolomide; grade
3 toxicity, 50% dose reduction in temozolomide; and grade 4
toxicity, 75% dose reduction in temozolomide. For grades 3
and 4 diarrhea, the dose of irinotecan was reduced by 25%
and 50%, respectively.
Statistical Analysis
The null hypothesis, that the overall response rate is
less than 10%, was tested and we estimated a response rate of
25% or greater for the combination of temozolomide and
irinotecan to be sufficient to warrant further study. Using the
Simon’s two-stage study design, 18 patients were recruited
during the first stage. If fewer than three responses were
observed, the study would be terminated. Conversely, if three
of more responses were observed, an additional 25 patients
were recruited. The null hypothesis would be rejected if there
were eight or more observed responses. With this design, the
probability of falsely rejecting the null hypothesis is 0.05
(one-sided alpha) and the probability of correctly rejecting
the null hypothesis if the true response rate of 25% is at least
0.80 (80% power). If the true response rate was only 10%, the
probability of early termination was 73%.
Progression-free survival was calculated as the time
from registration to the first observation of disease progres-
sion, relapse, or death, whichever came first. Survival time
was defined as the time between registration and death.
Survivorship was estimated as a function of time from reg-
istration using the Kaplan-Meier survivorship analysis. All
observed toxicities were recorded and summarized using
appropriate descriptive statistics.
RESULTS
Patient Characteristics
The trial was initiated in March of 2002, and the last
patient was enrolled in December of 2004. The first six
patients accrued tolerated the regimen well in the first cycle
without requiring dose reduction. One patient required a 25%
irinotecan dose reduction in cycle 2 as a result of grade 3
diarrhea. After determining that the regimen was well toler-
ated at the doses administered (temozolomide, orally, 75
mg/m2 daily on days 1–15; and irinotecan, intravenously, 100
mg/m2 on days 8 and 15 in a 21-day cycle), a total of 46
patients were enrolled onto the study at participating hospitals
of the University of Chicago Phase II Network. The partici-
pating patient characteristics are listed in Table 1.
The mean age was 60 years (range, 32–80 years). More
than 90% of patient had an Eastern Cooperative Oncology
Group performance status of 0 or 1. Adenocarcinoma was the
most common histologic subtype. The majority of patients
had stage IV metastatic disease at the time of enrollment and
the rest had recurrent or refractory stage IIIA or IIIB disease.
All patients were previously treated with a platinum-based
chemotherapy regimen. Brain metastases were present in nine
patients (19.6%). The median interval between the last dose
of platinum-based chemotherapy and registration on the trial
TABLE 1. Patient Baseline Demographics
Characteristics Value (%)
No. of patients 46
Age (yr)
Mean 60
Range 32–80
Male-to-female ratio 30/16
Race
White 32 (69.6)
African American 10 (21.7)
Asian 4 (8.7)
Performance status (ECOG)
0 17 (37.0)
1 26 (56.5)
2 3 (6.5)
Interval between prior platinum-based
chemotherapy and initiation of trial (mo)
Median 4
Range 1–28
Tumor histology
Adenocarcinoma 26 (56.5)
Squamous-cell carcinoma 6 (13.0)
Large-cell carcinoma 6 (13.0)
Poorly differentiated carcinoma 8 (17.4)
Stage at diagnosis
I 2 (4.3)
IIIA 4 (8.7)
IIIB 15 (32.6)
IV 25 (54.3)
Stage at enrollment
IIIA 4 (8.7)
IIIB 16 (34.8)
IV 26 (56.5)
Site of metastasis
Brain 9 (19.6)
Lymph node 34 (73.9)
Adrenal gland 11 (23.9)
Bone 15 (32.6)
Contralateral lung 6 (13.0)
Liver 3 (6.5)
No. of sites involved by metastasis
1 23 (50.0)
2 15 (32.6)
3 8 (17.4)
ECOG, Eastern Cooperative Oncology Group.
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was 4 months (range, 1–28 months). All patients with brain
metastases had been treated with whole-brain radiation ther-
apy and were clinically stable prior to starting the study.
Response and Survival
All patients were assessed for response and toxicity and
were included in the survival analysis. A total of 136 cycles
were administered, with a median number of two cycles per
patient (Table 2). Twelve patients (26.1%) completed six
cycles of treatment. Eleven patients (23.9%) received only
one treatment cycle. Clinical disease progression accounted
for nine patients discontinuing treatment after one cycle of
irinotecan/temozolomide. In the nine patients who received
only one cycle of irinotecan/temozolomide, two developed
worsening pleural effusions, four developed worsening respi-
ratory failure attributed to disease progression, two developed
new bone metastasis, and one developed new supraclavicular
lymphadenopathy. Two other patients discontinued therapy
after one cycle as a result of severe diarrhea requiring
hospitalization. One episode of diarrhea was attributed to
irinotecan and the other was a result of Clostridium difficile
infection.
As noted, 12 patients completed all six cycles of the
treatment regimen. Thirty-one patients (67.4%) were taken
off the study as a result of disease progression. Two patients
(4.3%) experienced significant adverse effects that led to their
being taken off the study, and only one patient voluntarily
withdrew participation from the study after experiencing C.
difficile infection.
All 46 patients enrolled were evaluated for response.
Four patients had a partial response (PR), for an overall
objective response rate of 8.7% (95% confidence interval
[CI], 3.4–20.3%). Three of the partial responses were ob-
served in the first 18 patients enrolled on the study. No
complete responses were observed. Seventeen patients
(37.0%) had disease stabilization as their best response. The
clinical benefit rate (PR  SD) was 45.7% for the entire
cohort.
Nine patients (19.6%) had stable and treated brain
metastasis at the time of enrollment. None of these patients
developed clinical progression of their previously treated
brain metastases or new central nervous system (CNS) me-
tastasis while on the study. Three patients (6.5%) without
prior brain metastasis developed new brain parenchymal
metastasis while on the study.
Intent-to-treat median time to progression was 1.8
months (95% CI, 1.5–3 months) as shown in Figure 1. At the
time of last follow-up in May of 2005, the intent-to-treat median
overall survival was 9.8 months (95%CI, 4.3–12.8 months). The
Kaplan-Meier survival curve is shown is Figure 2. One-year
overall survival rate was 34% (96% CI, 20–48.7%).
Information on the subsequent therapy or sequelae after
completing the study was available for only 37 patients
(80%). On completion of the study, 15 patients (32%) did not
receive any subsequent therapy and were referred for hospice
care. As detailed below, one patient (2%) died unexpectedly
while on the study. Thirteen patients (28%) subsequently
received an epidermal growth factor receptor tyrosine kinase
inhibitor, either gefitinib or erlotinib, and eight patients (17%)
received third-line cytotoxic chemotherapy, which included
single-agent gemcitabine, vinorelbine, or docetaxel.
Toxicity
The combination of temozolomide and irinotecan was
generally well tolerated (Table 3). The majority of toxicities
were mild (grade 1–2). During the course of the study, one
patient died unexpectedly during cycle 2, day 16, possibly
related to the treatment regimen. Pneumocystis jiroveci pneu-
monia occurred in one patient who was not taking cortico-
steroids. Two patients were taken off the study as a result of
intolerance to the regimen. Both of those patients developed
severe nausea, diarrhea, and dehydration after one and two
cycles of therapy, respectively. The major toxicities are listed
in Table 3.
TABLE 2. Response to Therapy and Survival
Value
Median No. of cycles 2
Reason for discontinuation
Completed six total cycles 12 (26.1)
Disease progression/death 31 (67.4)
Adverse effects 2 (4.3)
Withdrew consent 1 (2.2)
Response
Complete response 0 (0.0)
Partial response 4 (8.7)
Stable disease 17 (37.0)
Progressive disease 25 (54.3)
Median time to progression (mo) 1.8
Median survival (mo) 9.8
One-year survival 34%
FIGURE 1. Progression-free survival for all patients enrolled
in the study of temozolomide/irinotecan (n  46). Bars indi-
cate censored patients.
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Hematologic Toxicity
No grade 4 hematologic toxicities were seen. In gen-
eral, most hematologic toxicities were mild (grade 1 or 2).
Mild anemia was the predominant hematologic toxicity ob-
served, accounting for 63%.
Leukopenia, lymphopenia, and neutropenia occurred in
approximately 39%, 28%, and 22% of patients, respectively.
Six episodes of febrile neutropenia were observed in four
patients. In two of these patients, febrile neutropenia occurred
in cycle 5, leading to dose reduction. One other patient who
developed febrile neutropenia was intolerant of the regimen
secondary to nausea, vomiting, and diarrhea and was taken
off the study after only one cycle. The remaining patient with
febrile neutropenia developed febrile neutropenia in cycle 1
and again in cycle 2 despite a dose reduction.
Nonhematologic Toxicity
Fatigue was the predominant toxicity, occurring in
more than 70% of patients. Most cases of fatigue were mild.
There was only one episode of grade 4 fatigue observed in the
study where the patient had clinical disease progression after
one cycle.
Diarrhea was observed in more than 50% of patients
but was generally mild. Of four patients with grade 3 diar-
rhea, one patient was taken off the study after developing
severe diarrhea in cycle 1, whereas the other three patients
tolerated a reduced dose of irinotecan in subsequent cycles.
Nausea and vomiting were commonly observed, occur-
ring in up to 59% and 41% of patients, respectively. Only
approximately 10% of the cases of nausea and vomiting were
grade 3. Nausea and vomiting arising from this regimen were
easily managed and prevented with standard antiemetics.
DISCUSSION
In this study, we demonstrated that the combination has
activity as a second-line combination regimen in NSCLC.
The response rate of 8.7% and disease control rate (PR SD)
of 45.7% appears similar to that of single-agent docetaxel3 or
pemetrexed.4 For our regimen, the median number of treat-
ment cycles was two and median time to progression was 1.8
months, compared with single-agent docetaxel or pem-
etrexed, where the median number of treatment cycles was
four and the median time to progression was approximately 3
months.4 However, the median overall survival of 9.8 months
and the 1-year overall survival rate of 34% are comparable to
those of other standard second-line therapies.4,5
Approximately 30 to 40% of NSCLC patients develop
brain metastasis.6,7 This results in significant morbidity as a
result of the metastasis itself and treatment-related toxicities.
Brain metastases from a variety of solid tumors including
NSCLC have been responsive to temozolomide administered
as monotherapy.13,14 In addition, recent data have shown that
6 months of adjuvant temozolomide was associated with a
survival advantage in patients with surgically resected glio-
blastoma.42 In our study, three patients without prior known
CNS lesions developed brain metastasis while on the study.
However, patients who had treated brain metastasis before
receiving temozolomide/irinotecan did not develop new le-
sions in the CNS clinically. This suggests that temozolomide
has little role in prophylaxis against brain metastasis in
NSCLC. Conversely, in trials evaluating second-line thera-
pies in NSCLC, the sites of treatment failure in particular
CNS metastasis are not well described. Furthermore, because
the median duration of therapy was only two cycles, there
may have been preexisting asymptomatic brain metastasis
before the initiation of the study in the patients who were
found to have brain metastasis. Because patients on the study
were not required to undergo head computed tomographic
evaluation unless deemed clinically necessary, the study does
not address the role of temozolomide in preventing recur-
rence in previously irradiated or resected CNS sites.
FIGURE 2. Overall survival for all patients enrolled in the
study of temozolomide/irinotecan (n  46). Survival time
was calculated from the date on which patients were en-
tered into the study. Bars indicate censored patients.
TABLE 3. Major Toxicity
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Total (%)
Hematologic toxicities
Anemia 18 10 1 0 29 (63.0)
Leukopenia 6 8 4 0 18 (39.1)
Lymphopenia 1 9 3 0 13 (28.3)
Neutropenia 2 7 1 0 10 (21.7)
Thrombocytopenia 2 0 2 0 4 (8.7)
Nonhematologic toxicities
Fatigue 19 10 3 1 33 (71.7)
Pain 15 10 3 0 28 (60.9)
Nausea 16 8 3 0 27 (58.7)
Diarrhea 15 5 4 0 24 (52.2)
Hyperglycemia 13 6 1 0 20 (43.5)
Vomiting 10 7 2 0 19 (41.3)
Anorexia 11 7 0 0 18 (39.1)
Constipation 13 1 1 0 15 (32.6)
Hyponatremia 11 0 2 0 13 (28.3)
Hypoalbuminemia 6 5 1 0 12 (26.1)
Alopecia 5 7 0 0 12 (26.1)
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CONCLUSION
In conclusion, we showed that temozolomide and iri-
notecan is a modestly active second-line regimen in NSCLC.
However, the response rate of approximately 9% demon-
strated in the current trial is consistent with our null hypoth-
esis. The toxicity profile of temozolomide and irinotecan was
favorable and most toxicities were mild (grade 1 or 2). Given
the availability of other currently approved agents in the
second-line treatment setting for NSCLC, this combination
does not warrant further investigations as studied here.
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